Fibronectin as a Prognostic Indicator in Portal Hypertension by Mckee, Ruth F. et al.
HPB Surgery, 1992, Vol. 5, pp. 229-234
Reprints available directly from the publisher
Photocopying permitted by license only
1992 Harwood Academic Publishers GmbH
Printed in the United Kingdom
FIBRONECTIN AS A PROGNOSTIC INDICATOR IN
PORTAL HYPERTENSION
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University Department of Surgery and Department of Haematology, Royal
Infirmary, Glasgow, UK
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Plasma fibronectin levels were measured in 33 patients with portal hypertension and c6mpared with
modified Child’s grading and a previously described prognostic index. Outcome at one year from blood
sampling was recorded.
Mean plasma fibronectin level was 304.1 mg/ml (sem 24.3) and significantly lower levels were found in
patients who had had a variceal bleed within the previous seven days. Plasma fibronectin levels tended
to be lower in patients with poor liver function as assessed by modified Child’s grading but this did not
achieve statistical significance.
Plasma fibronectin alone was not an accurate predictor of one year survival in these patients but only
one of seven patients who had a plasma fibronectin level below 300mg/l in association with a poor
prognostic index survived for one year.
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INTRODUCTION
Fibronectin is a glycoprotein which is produced by vascular endothelial cells,
fibroblasts and hepatocytes and is thought to function as an opsonin during
phagocytosis. Low fibronectin levels have been associated with poor survival in
patients with sepsis and trauma2.
Abnormal levels of plasma fibronectin have been found in patients with liver
disease. Whereas increased levels have been found in uncomplicated acute
hepatitis3’4, low levels were noted in patients with fulminant hepatic failure5.
Cirrhotic patients with portal hypertension have been reported to have low levels of
plasma fibronectin and it has been suggested that plasma fibronectin level corre-
lates with survival in these patients7.
The aim of this study was to assess plasma fibronectin levels in a variety of portal
hypertensive patients, to determine whether plasma fibronectin was related to the
severity of liver disease as assessed by Pugh’s modification of Child’s grading and a
previously reported prognostic index9, and to relate plasma fibronectin level to
prognosis.
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PATIENTS AND METHODS
Thirty-three patients with portal hypertension and a history of bleeding oesopha-
geal varices were studied. Details of the patients’ age, sex, liver disease and
modified Child’s grading are shown in Table 1. All patients had endoscopically
proven oesophageal varices and the presence of liver disease was confirmed on the
basis of history, clinical findings and by liver biopsy, when the coagulation screen
allowed this, or isotope liver scan. Only one patient had undergone portacaval
shunting previously and this shunt was known to be thrombosed at the time of
study. Splenectomy had been performed in two other patients. Plasma samples
were obtained from 33 patients during the patient’s first admission to hospital
during the study period, either following a variceal bleed
13 or for elective
sclerotherapy2. In thirteen patients repeat plasma fibronectin samples were
obtained during a subsequent admission at least four weeks after the first sample
had been taken. Blood samples were spun down immediately and stored at
20SOT, 4C until analysis could be performed. Immunological levels of fibronectin
were then measured using a turbidometric method (Boehringer-Mannheim Kit No
401218).
At the time of removal of each plasma sample details of the patient’s current
clinical findings, full blood count, coagulation screen, urea and electrolytes, glucose
and liver function tests were recorded. Liver function was assessed by Pugh’s
modification of Child’s grading and by the use of a prognostic index9. To obtain
this index the probability of 1 year survival(p) was calculated using the equation
ln(p/(1-p)) 7.8 0.76ENC 2.7PTR- 0.05CR
Table 1 Patient details divided with regard to whether they had experienced a variceal bleed in the
seven days prior to initial blood sampling or not
Modified
Age Sex ratio Aetiology Child’s Grading
Acute
Stable
Total
60.3 11" 2 10 Alcohol cirrhosis 2-A: 3-B: 8-C
Primary biliar cirrhosis
Chronic active heptatitis
Drug induced cirrhosis
57.3 13" 7 12 Alcoholic cirrhosis 8-A: 8-B: 4-C
4 Primary biliary cirrhosis
Chronic active hepatitis
2 Cryptogenic cirrhosis
Portal vein thrombosis
58.5 24:9 22 Alcoholic cirrhosis 10-A: ll-B: 12-C
5 Primary biliary cirrhosis
2 Chronic active hepatitis
2 Cryptogenic cirrhosis
Drug induced cirrhosis
Portal vein thrombosisFIBRONECTIN IN PORTAL HYPERTENSION 231
where the actual values of prothrombin ratio(PTR) and creatinine(CR) are entered
and encephalopathy(ENC) is coded as -1 when absent and + 1 when present. The
date of the most recent variceal bleed was noted, along with any treatment
necessary, in particular recent blood or blood product transfusions and injection
sclerotherapy. A recent acute bleed was defined as haematemesis or melaena in the
previous seven days causing either shock (pulse rate > 100; systolic blood pressure
< 100), a fall in haemoglobin to less than 10g/dl or a drop in haemogl6bin level of
3g within 48 hours. Survival was assessed for each patient from the first admission
to hospital while in the study and for at least one year after this admission.
Unpaired t-tests were used for comparison of plasma fibronectin levels in
different groups of patients. Paired t-tests were used to compare two successive
fibronectin and prognostic index measurements in 13 patients.
RESULTS
The mean initial plasma fibronectin for all patients was 304.1mg/1.(sem 24.3) Only
two patients had plasma fibronectin levels below the normal range for our
laboratory (140-490mg/1). The mean fibronectin level in the group of patients
within seven days of a variceal bleed was 236.8mg/1 (sem 29.1, n 13) compared to
347.8mg/1 (sem 32.2, n 20) in the group of stable patients. The difference between
these two groups was significant (t 2.39, p< 0.05). A low plasma fibronectin level
was not associated with clinical findings of ascites or splenomegaly. Plasma
fibronectin level varied with liver function, the mean fibronectin level in modified
Child’s A and B patients being 327.5mg/1 (sem 31.9, n=21) while in modified
Child’s C patients the mean fibronectin level was 263mg/1 (sem 35, n= 12).
However, this difference was not statistically significant. Plasma fibronectin level
did not correlate with prognostic index (Figure 1; r=-0.1).
Three patients died during the index admission for this study, all following a
variceal bleed. A further eight patients died during the next year, twenty-two
patients survived. Two of these patients died of causes unrelated to their liver
disease. The level of plasma fibronectin alone was not an accurate predictor of
survival over the following year (Figure 2), although the mean plasma fibronectin in
one year survivors (337.5mg/1, sem 32.3) was significantly higher than in those
patients who died (237.2mg/1, sem 24.6: t=2.47, p<0.01). However plasma
fibronectin level and prognostic index together gave good prediction of 1 year
survival (Figure 1). Of seven patients who had a plasma fibronectin level of less
than 300mg/1 along with a prognostic index of less than 0.5, six died over the next
twelve months.
When the 13 patients with repeat plasma fibronectin samples were studied, in
nine patients who were stable on both admissions there was no significant
difference between the value of prognostic index or plasma fibronectin (mean first
fibronectin value 337.5mg/1 sem 67.5; mean second fibronectin 303.3mg/1 sem
39.0; 0.56; p< 0.5).
DISCUSSION
Few portal hypertensive patients in the present study had plasma fibronectin levels232 R.F. McKEE ET AL.
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Figure 1 Plasma fibronectin level (mg/l) and prognostic index (9) in 33 patients with portal hyperten-
sion. Patients who survived to one year after blood sampling shown as crosses + ), patients who died
within one year shown as closed circles (o).
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Figure 2 Plasma fibronectin level compared to one year survival in 33 patients with portal hypertension.FIBRONECTIN IN PORTAL HYPERTENSION 233
below the normal range. Although Foster and colleagues
6 found reduced plasma
fibronectin levels in portal hypertension Gluud’s group
4 could not confirm this
finding and Matsuda and colleagues could only show a reduction in plasma
fibronectin in patients with decompensated cirrhosis. Although some of our
patients had severe hepatic decompensation with ascites, encephalopathy and
grossly abnormal liver function, the majority had apparently well preserved liver
function, as assessed by modified Child’s grading. There was a tendency towards
lower plasma fibronectin values in grade C patients although this was not signifi-
cantly different from grade A and B patients. Plasma fibronectin has also been
shown to be raised in acute hepatitis
3,4 and these variations in liver function may
account for the wide range of plasma fibronectin levels in our patients.
In the present study, plasma fibronectin levels have been found to be lower
following recent variceal haemorrhage. Blood in the gastrointestinal tract might
lead to changes in the bacterial population and the associated hypotension might
lead to episodes of endotoxaemia during variceal haemorrhage. In a recent
preliminary study we have demonstrated endotoxaemia in several patients during
the 48 hours after a variceal bleed. The depletion in plasma fibronectin levels may
therefore result from its use in increased reticulo-endothelial system activity.
We have been unable to show that plasma fibronectin alone is an accurate
indicator of survival in patients with portal hypertension. In these patients many
factors are involved in determining prognosis and it seems unlikely that a single
variable can predict outcome accurately in a heterogenous group of portal hyper-
tensive patients. It is difficult to separate the effects of a variceal bleed, poor liver
function and any other variable which might affect outcome as these variables are
interrelated.
Nonetheless the combination of low plasma fibronectin and a low prognostic
index was associated with a very poor prognosis (Figure 1). In this study, stable
patients have been included as well as patients who had had a recent variceal bleed
and this may explain the reduction in the accuracy of predicting prognosis from
81% to 68% when the prognostic index is used alone. However when prognostic
index and plasma fibronectin level are taken together only one of the seven patients
with a prognostic index of less than 0.5 and plasma fibronectin level of less than
300mg/1 survived to one year. Since fibronectin acts as an opsonin in the reticulo-
endothelial system it is not surprising that low levels of this glycoprotein in
association with indicators of poor hepatic and renal function are associated with a
poor prognosis in portal hypertension.
In conclusion, we have shown that in a heterogenous group of patients with
portal hypertension there is a wide range of plasma fibronectin levels, and this may
be due to differeing degrees of hepatic decompensation and hepatitis. A recent
variceal bleed is associated with lower plasma fibronectin levels.
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